Viatris | VTRS - Des Atouts





Des Atouts Changement Date
Celltrion KRW 768.81B 9.37B 2026-03
Cspc Pharmaceutical CNY 46.7B 695.56M 2025-12
Deva Holding AS TRY 12.93B 1.83B 2023-09
Dianthus Therapeutics USD 1.21B 33.61M 2026-06
Divis Laboratories Ltd INR 200.33B 18.82B 2026-03
Kangmei Pharma CNY 13.31B 375.64M 2026-03
Knight Therapeutics CAD 1.05B 2.28M 2025-12
Laboratorios Farma EUR 799.88M 99.95M 2023-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Medical Developments International AUD 63.57M 2.83M 2025-12
Neuren Pharmaceuticals AUD 342.86M 11.61M 2025-12
Organigram Holdings CAD 521.31M 9.36M 2026-03
Ovoca Bio EUR 2.07M 414K 2025-12
Pharma Mar EUR 393.6M 8.34M 2026-06
Qiagen NV USD 5.89B 107.14M 2026-06
Sartorius EUR 9.6B 270.6M 2026-06
Sino Biopharmaceutical CNY 74.89B 9.49B 2025-06
Tilray USD 2.1B 15.95M 2025-09
Viatris USD 35.04B 1.79B 2026-06
Zealand Pharma A/S 15.3B 647.8M 2026-03
Zz Pientze Pharmaceu CNY 18.51B 129.02M 2026-06